Cellares, a contract developer and manufacturer, has announced a partnership with Taiwan-based GenomeFrontier Therapeutics to explore the use of its automated Cell Shuttle platform for producing virus-free CAR-T therapies. The evaluation will focus on whether the integrated system can handle the specific requirements of virus-free manufacturing, which avoids the use of viral vectors for gene delivery.
GenomeFrontier's approach to CAR-Ts relies on non-viral methods, potentially offering safety and cost advantages over traditional viral-based production. By combining this with Cellares' automation, the companies hope to demonstrate a more scalable and reproducible manufacturing process.
This is a single-source announcement, so no independent verification or contrasting views are available. The outcome of the evaluation could inform future adoption of automated platforms for virus-free cell therapies, but no timeline or specific success metrics were disclosed in the source.